Evidence map›Paper›PMID 40371846›Full record

ArticleCancer medicine2025

Transcutaneous Imiquimod Combined With Anti-Programmed Cell Death-1 Monoclonal Antibody Extends the Survival of Mice Bearing Renal Cell Carcinoma.

Takashi Karashima, Toshihiro Komatsu, Shinkuro Yamamoto, Kaya Atagi, Hatsune Hashida, Hideo Fukuhara, Kenji Tamura, Shingo Ashida, Taro Shuin, Keiko Udaka and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Takashi KarashimaDepartment of Urology, Kochi Medical School, Nankoku, Japan.ORCID https://orcid.org/0000-0001-7338-8059
Toshihiro KomatsuDepartment of Immunology, Kochi Medical School, Nankoku, Japan.
Shinkuro YamamotoDepartment of Urology, Kochi Medical School, Nankoku, Japan.
Kaya AtagiDepartment of Urology, Kochi Medical School, Nankoku, Japan.
Hatsune HashidaDepartment of Urology, Kochi Medical School, Nankoku, Japan.
Hideo FukuharaDepartment of Urology, Kochi Medical School, Nankoku, Japan.
Kenji TamuraDepartment of Urology, Kochi Medical School, Nankoku, Japan.
Shingo AshidaDepartment of Urology, Kochi Medical School, Nankoku, Japan.
Taro ShuinDepartment of Urology, Kochi Medical School, Nankoku, Japan.
Keiko UdakaDepartment of Immunology, Kochi Medical School, Nankoku, Japan.
Takahiro ShimizuDepartment Pharmacology, Kochi Medical School, Nankoku, Japan.
Motoaki SaitoDepartment Pharmacology, Kochi Medical School, Nankoku, Japan.
Nobutaka ShimizuCenter for Pelvic Floor, Kochi Medical School Hospital, Nankoku, Japan.
Keiji InoueDepartment of Urology, Kochi Medical School, Nankoku, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeImiquimod (IQM), an imidazoquinoline derivative, is an immunomodulator that activates an adaptive immune response. IQM is applied topically for genital warts and actinic keratosis. Programmed cell death-1 (PD-1) suppresses activated T cells by binding to programmed cell death-ligand 1 and programmed cell death-ligand 2, braking antitumor immunity. Anti-PD-1 therapy has been used for various malignant neoplasms including renal cell carcinoma (RCC). Whether combination therapy with transcutaneous administration of IQM cream and intraperitoneal administration of anti-PD-1 monoclonal antibody (mAb) suppresses mouse RCC cells growing in subcutaneous tissue was investigated.

methodsFemale BALB/c mice were implanted subcutaneously with 2 × 10

resultsCombination therapy with IQM and anti-PD-1 mAb significantly suppressed tumor growth compared to each monotherapy and prolonged the survival of the mice. The combination therapy produced more RENCA tumor-specific IgG than either IQM or anti-PD-1 mAb alone. The percentage of the CD44

conclusionsThe present results show that combination therapy with IQM and anti-PD-1 mAb might be a promising novel therapeutic strategy for advanced RCC.

Indexed as

Antibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Renal CellImiquimodImmune Checkpoint InhibitorsKidney NeoplasmsProgrammed Cell Death 1 ReceptorAdministration, CutaneousAnimalsCD8-Positive T-LymphocytesCell Line, TumorFemaleMiceMice, Inbred BALB CAntibodies, MonoclonalImiquimodImmune Checkpoint InhibitorsPdcd1 protein, mouseProgrammed Cell Death 1 ReceptorIgGimiquimodimmune checkpoint inhibitorprogrammed cell death‐1renal cell carcinomaspleenT cell

Identifiers

PMID40371846
PMCPMC12079644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.